Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials

Rossing, P; Inzucchi, SE; Vart, P; Jongs, N; Docherty, KF; Jhund, PS; Kober, L; Kosiborod, MN; Martinez, FA; Ponikowski, P; Sabatine, MS; Solomon, SD; DeMets, DL; Bengtsson, O; Lindberg, M; Langkilde, AM; Sjostrand, M; Stefansson, BV; Karlsson, C; Chertow, GM; Hou, FF; Correa-Rotter, R; Toto, RD; Wheeler, DC; McMurray, JJV; Heerspink, HJL

Heerspink, HJL (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, NL-9700 AD Groningen, Netherlands.

LANCET DIABETES & ENDOCRINOLOGY, 2022; 10 (1): 24

Abstract

Background Chronic kidney disease and heart failure are insulin resistant states associated with a high incidence of diabetes. We assessed the effect ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索